No medication prescription and residential distance from the hospital are important factors associated with nonsurgical weight-loss treatment discontinuance in Japanese patients with high-degree obesity: a retrospective study.
Humans
Retrospective Studies
Male
Female
Japan
Middle Aged
Adult
Body Mass Index
Obesity
/ therapy
Anti-Obesity Agents
/ therapeutic use
Weight Loss
Aged
Weight Reduction Programs
/ statistics & numerical data
Patient Dropouts
/ statistics & numerical data
Health Services Accessibility
/ statistics & numerical data
East Asian People
Dropout
High-degree obesity
Medication
Residential distance
Telemedicine
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
16 Sep 2024
16 Sep 2024
Historique:
received:
13
11
2022
accepted:
21
08
2024
medline:
17
9
2024
pubmed:
17
9
2024
entrez:
16
9
2024
Statut:
epublish
Résumé
Although the percentage of the population with a high degree of obesity (body mass index [BMI] ≥ 35 kg/m We retrospectively reviewed the medical charts of 271 Japanese patients with high-degree obesity who presented at Toho University Sakura Medical Center for obesity treatment between April 1, 2014, and December 31, 2017. The patients were divided into non-dropout and dropout groups. Patients who discontinued weight-loss treatment within 24 months of the first visit were defined as "dropouts." Multivariate Cox proportional hazards regression analysis and Kaplan-Meier survival analysis were performed to examine the factors predicting treatment withdrawal. Among the 271 patients, 119 (43.9%) discontinued treatment within 24 months of the first visit. The decrease in BMI did not significantly differ between the two groups. No prescription of medication and residential distance from the hospital exceeding 15 km were the top contributors to treatment discontinuation, and the absence of prescription medication was the most important factor. The dropout-free rate was significantly higher in patients with medication prescriptions than in those without and in patients who lived within 15 km of the hospital than in those who lived farther than 15 km from the hospital. No medication prescription and longer residential distance from the hospital were associated with treatment dropout in Japanese patients with high-degree obesity; therefore, the addition of antiobesity medications and telemedicine may be necessary to prevent treatment discontinuation in such patients.
Sections du résumé
BACKGROUND
BACKGROUND
Although the percentage of the population with a high degree of obesity (body mass index [BMI] ≥ 35 kg/m
METHODS
METHODS
We retrospectively reviewed the medical charts of 271 Japanese patients with high-degree obesity who presented at Toho University Sakura Medical Center for obesity treatment between April 1, 2014, and December 31, 2017. The patients were divided into non-dropout and dropout groups. Patients who discontinued weight-loss treatment within 24 months of the first visit were defined as "dropouts." Multivariate Cox proportional hazards regression analysis and Kaplan-Meier survival analysis were performed to examine the factors predicting treatment withdrawal.
RESULTS
RESULTS
Among the 271 patients, 119 (43.9%) discontinued treatment within 24 months of the first visit. The decrease in BMI did not significantly differ between the two groups. No prescription of medication and residential distance from the hospital exceeding 15 km were the top contributors to treatment discontinuation, and the absence of prescription medication was the most important factor. The dropout-free rate was significantly higher in patients with medication prescriptions than in those without and in patients who lived within 15 km of the hospital than in those who lived farther than 15 km from the hospital.
CONCLUSIONS
CONCLUSIONS
No medication prescription and longer residential distance from the hospital were associated with treatment dropout in Japanese patients with high-degree obesity; therefore, the addition of antiobesity medications and telemedicine may be necessary to prevent treatment discontinuation in such patients.
Identifiants
pubmed: 39285392
doi: 10.1186/s12913-024-11474-2
pii: 10.1186/s12913-024-11474-2
doi:
Substances chimiques
Anti-Obesity Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1078Informations de copyright
© 2024. The Author(s).
Références
Ogawa W, Hirota Y, Miyazaki S, Nakamura T, Ogawa Y, Shimomura I, et al. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J. 2024;71(3):223–31.
doi: 10.1507/endocrj.EJ23-0593
pubmed: 38123337
Sasaki A, Wakabayashi G, Yonei Y. Current status of bariatric surgery in Japan and effectiveness in obesity and diabetes. J Gastroenterol. 2014;49(1):57–63.
doi: 10.1007/s00535-013-0802-5
pubmed: 23595611
Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet. 2002;360(9328):235.
doi: 10.1016/S0140-6736(02)09512-0
pubmed: 12133671
Kuwabara M, Kuwabara R, Niwa K, Hisatome I, Smits G, Roncal-Jimenez CA, et al. Different risk for hypertension, diabetes, Dyslipidemia, and Hyperuricemia according to level of body Mass Index in Japanese and American subjects. Nutrients. 2018;10(8):1011.
doi: 10.3390/nu10081011
pubmed: 30081468
pmcid: 6115805
Ohira M, Yamaguchi T, Saiki A, Nakamura S, Tanaka S, Oka R, et al. Laparoscopic sleeve gastrectomy significantly increases serum lipoprotein lipase level in obese patients. Obes Facts. 2019;12:357–68.
doi: 10.1159/000500360
pubmed: 31167211
pmcid: 6696888
Watanabe Y, Yamaguchi T, Yamaoka S, Abe K, Onda H, Nakamura S, et al. Effect of conventional medical therapy or laparoscopic sleeve gastrectomy on urinary albumin in Japanese subjects with severe obesity: an observational study. Obes Facts. 2021;14:613–21.
doi: 10.1159/000519156
pubmed: 34649255
pmcid: 8740108
Colombo O, Ferretti VV, Ferraris C, et al. Is drop-out from obesity treatment a predictable and preventable event? Nutr J. 2014;13:13.
doi: 10.1186/1475-2891-13-13
pubmed: 24490952
pmcid: 3914843
Benediktsdottir A, Halldorsson TI, Bragadottir GJ, Gudmundsson L, Ramel A. Predictors of dropout and bariatric surgery in Icelandic morbidly obese female patients. Obes Res Clin Pract. 2016;10:63–9.
doi: 10.1016/j.orcp.2015.03.009
pubmed: 25892541
Batterham M, Tapsell LC, Charlton KE. Predicting dropout in dietary weight loss trials using demographic and early weight change characteristics: implications for trial design. Obes Res Clin Pract. 2016;10:189–96.
doi: 10.1016/j.orcp.2015.05.005
pubmed: 26044614
Sweeting AN, Hocking SL, Markovic TP. Pharmacotherapy for the treatment of obesity. Mol Cell Endocrinol. 2015;418:173–83.
doi: 10.1016/j.mce.2015.09.005
pubmed: 26360586
Kubo T. Common approach to childhood obesity in Japan. J Pediatr Endocrinol Metab. 2014;27:581–92.
doi: 10.1515/jpem-2014-0047
pubmed: 24810559
Cignarella A, Busetto L, Vettor R. Pharmacotherapy of obesity: an update. Pharmacol Res. 2021;169:105649.
doi: 10.1016/j.phrs.2021.105649
pubmed: 33962014
Moreno B, Crujeiras AB, Bellido D, Sajoux I, Casanueva FF. Obesity treatment by very low-calorie-ketogenic diet at two years: reduction in visceral fat and on the burden of disease. Endocrine. 2016;54:681–90.
doi: 10.1007/s12020-016-1050-2
pubmed: 27623967
Kaikkonen KM, Saltevo SS, Korpelainen JT, Vanhala ML, Jokelainen JJ, Korpelainen RI, et al. Effective weight loss and maintenance by intensive start with diet and exercise. Med Sci Sports Exerc. 2019;51:920–9.
doi: 10.1249/MSS.0000000000001855
pubmed: 30531489
Katzmarzyk PT, Martin CK, Newton RL Jr, Apolzan JW, Arnold CL, Davis TC, et al. Weight loss in underserved patients – A cluster-randomized trial. N Engl J Med. 2020;383:909–18.
doi: 10.1056/NEJMoa2007448
pubmed: 32877581
pmcid: 7493523
Virani SS, Morris PB, Agarwala A, Ballantyne CM, Birtcher KK, Kris-Etherton PM, et al. 2021 ACC Expert Consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol. 2021;78:960–93.
doi: 10.1016/j.jacc.2021.06.011
pubmed: 34332805
Luccheta RC, Riveros BS, Pontarolo R, Radominski RB, Otuki MF, Fernandez-Llimos F, et al. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clin (Sao Paulo). 2017;72:317–24.
doi: 10.6061/clinics/2017(05)10
Slama G, Selmi A, Hautecouverture M, Tchobroutsky G. Double blind clinical trial of mazindol on weight loss blood glucose, plasma insulin and serum lipids in overweight diabetic patients. Diabete Metab. 1978;4:193–9.
pubmed: 361463
Walker BR, Ballard IM, Gold JA. A multicentre study comparing mazindol and placebo in obese patients. J Int Med Res. 1977;5:85–90.
doi: 10.1177/030006057700500202
pubmed: 326596
Perna S, Spadaccini D, Riva A, Allegrini P, Edera C, Faliva MA, et al. A path model analysis on predictors of dropout (at 6 and 12 months) during the weight loss interventions in endocrinology outpatient division. Endocrine. 2018;61:447–61.
doi: 10.1007/s12020-018-1563-y
pubmed: 29470776
Atlantis E, Lin F, Anandabaskaran S, Fahey P, Kormas N. A predictive model for non-completion of an intensive specialist obesity service in a public hospital: a case-control study. BMC Health Serv Res. 2019;19:748.
doi: 10.1186/s12913-019-4531-1
pubmed: 31651309
pmcid: 6814104
Inelmen EM, Toffanello ED, Enzi G, Gasparini G, Miotto F, Sergi G, et al. Predictors of drop-out in overweight and obese outpatients. Int J Obes (Lond). 2005;29:122–8.
doi: 10.1038/sj.ijo.0802846
pubmed: 15545976
Yackobovitch-Gavan M, Steinberg DM, Endevelt R, Benyamini Y. Factors associated with dropout in a group weight-loss programme: a longitudinal investigation. J Hum Nutr Diet. 2015;28(Suppl 2):33–40.
doi: 10.1111/jhn.12220
pubmed: 24528102
Grossi E, Dalle Grave R, Mannucci E, Molinari E, Compare A, Cuzzolaro M, et al. Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. Int J Obes (Lond). 2006;30:1132–7.
doi: 10.1038/sj.ijo.0803244
pubmed: 16432536
Dalle Grave R, Melchionda N, Calugi S, Centis E, Tufano A, Fatati G, et al. Continuous care in the treatment of obesity: an observational multicentre study. J Intern Med. 2005;258:265–73.
doi: 10.1111/j.1365-2796.2005.01524.x
pubmed: 16115301
Hadžiabdić MO, Mucalo I, Hrabač P, Matić T, Rahelić D, Božikov V. Factors predictive of drop-out and weight loss success in weight management of obese patients. J Hum Nutr Diet. 2015;28(Suppl 2):24–32.
doi: 10.1111/jhn.12270
pubmed: 25220046
Honas JJ, Early JL, Frederickson DD, O’Brien MS. Predictors of attrition in a large clinic-based weight-loss program. Obes Res. 2003;11:888–94.
doi: 10.1038/oby.2003.122
pubmed: 12855759
Dalle Grave R, Calugi S, Molinari E, Petroni ML, Bondi M, Compare A, et al. Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. Obes Res. 2005;13:1961–9.
doi: 10.1038/oby.2005.241
pubmed: 16339128
Ahrendt AD, Kattelmann KK, Rector TS, Maddox DA. The effectiveness of telemedicine for weight management in the MOVE! Program. J Rural Health. 2014;30:113–9.
doi: 10.1111/jrh.12049
pubmed: 24112223
Hansel B, Giral P, Gambotti L, Lafourcade A, Peres G, Filipecki C, et al. A fully automated web-based program improves lifestyle habits and HbA1c in patients with type 2 diabetes and abdominal obesity: randomized trial of patient e-coaching nutritional support (the ANODE study). J Med Internet Res. 2017;19:e360. https://doi.org/10.2196/jmir.7947
doi: 10.2196/jmir.7947
pubmed: 29117929
pmcid: 5700402